Publication | Closed Access

Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy

Hematological MalignancyImmunologyTumor ImmunityHematologyMyelopoiesisAutoimmunityCell BiologyAnti-pd-1/pd-l1 Treatment EfficacyImmunotherapyMedicineCell TransplantationTumor BiologyMyeloid Neoplasia